Angiodynamics (ANGO) Cost of Revenue (2016 - 2026)
Angiodynamics' Cost of Revenue history spans 17 years, with the latest figure at $36.9 million for Q1 2026.
- For Q1 2026, Cost of Revenue rose 44.86% year-over-year to $36.9 million; the TTM value through Feb 2026 reached $123.9 million, up 8.42%, while the annual FY2025 figure was $103.1 million, 30.88% down from the prior year.
- Cost of Revenue reached $36.9 million in Q1 2026 per ANGO's latest filing, up from $26.7 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $82.0 million in Q2 2022 to a low of -$15.5 million in Q2 2023.
- Average Cost of Revenue over 5 years is $30.8 million, with a median of $27.4 million recorded in 2023.
- Peak YoY movement for Cost of Revenue: tumbled 118.95% in 2023, then skyrocketed 308.89% in 2024.
- A 5-year view of Cost of Revenue shows it stood at $26.0 million in 2022, then decreased by 2.09% to $25.5 million in 2023, then rose by 0.49% to $25.6 million in 2024, then increased by 4.38% to $26.7 million in 2025, then soared by 38.31% to $36.9 million in 2026.
- Per Business Quant, the three most recent readings for ANGO's Cost of Revenue are $36.9 million (Q1 2026), $26.7 million (Q4 2025), and $33.9 million (Q3 2025).